Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications

Shen Chieh Chang, Winston W. Shen

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.

Original languageEnglish
Pages (from-to)210-216
Number of pages7
JournalJournal of Experimental and Clinical Medicine(Taiwan)
Volume5
Issue number6
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Wakefulness-Promoting Agents
Narcolepsy
Attention Deficit Disorder with Hyperactivity
Circadian Rhythm Sleep Disorders
Guanfacine
Methylphenidate
Methamphetamine
Clonidine
Obstructive Sleep Apnea
Amphetamine
United States Food and Drug Administration
Pharmaceutical Preparations
Psychiatry
Norepinephrine
History
Therapeutics

Keywords

  • Attention deficit hyperactivity disorder
  • Modafinil
  • Narcolepsy
  • Stimulants

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{d2d2d340f4124417a077262fb0a77cc0,
title = "Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications",
abstract = "The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.",
keywords = "Attention deficit hyperactivity disorder, Modafinil, Narcolepsy, Stimulants",
author = "Chang, {Shen Chieh} and Shen, {Winston W.}",
year = "2013",
month = "12",
doi = "10.1016/j.jecm.2013.10.010",
language = "English",
volume = "5",
pages = "210--216",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications

AU - Chang, Shen Chieh

AU - Shen, Winston W.

PY - 2013/12

Y1 - 2013/12

N2 - The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.

AB - The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.

KW - Attention deficit hyperactivity disorder

KW - Modafinil

KW - Narcolepsy

KW - Stimulants

UR - http://www.scopus.com/inward/record.url?scp=84890791157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890791157&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2013.10.010

DO - 10.1016/j.jecm.2013.10.010

M3 - Review article

VL - 5

SP - 210

EP - 216

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 6

ER -